Citigroup Maintains Buy on Silk Road Medical, Lowers Price Target to $35
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Joanne Wuensch has maintained a 'Buy' rating on Silk Road Medical (NASDAQ:SILK) but lowered the price target from $48 to $35.
August 14, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Citigroup has maintained a 'Buy' rating on Silk Road Medical but lowered the price target from $48 to $35.
The news is directly related to Silk Road Medical. While the 'Buy' rating is maintained, the lowering of the price target might indicate a potential decrease in the stock's value. However, the impact on the stock price is uncertain in the short term as the 'Buy' rating might still attract investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100